title: Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook.
abstract: In this review, we outline the pathophysiology of severe asthma and discuss the role of anti-interleukin (IL)-5 inhibitors for the treatment of asthma. Anti-IL-5 treatments have shown efficacy in reducing the rate of severe asthma attacks in eosinophilic asthma. We review the history of the development of these agents, lessons learnt about severe asthma along the way and key clinical trials supporting efficacy of the three anti-IL-5 treatments that are clinically available or undergoing clinical trials in asthma.
authors.affiliation: Nuffield Department of Medicine, University of Oxford, NDM Research Building, Old Road Campus, Oxford, OX3 7FZ, UK.
authors.forename: Rahul
authors.initials: R
authors.lastname: Shrimanker
authors.affiliation: Nuffield Department of Medicine, University of Oxford, NDM Research Building, Old Road Campus, Oxford, OX3 7FZ, UK. Ian.pavord@ndm.ox.ac.uk.
authors.forename: Ian D
authors.initials: ID
authors.lastname: Pavord
mesh_terms: D018927:Anti-Asthmatic Agents / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D004804:Eosinophils / Q000187:drug effects / Q000473:pathology; D006801:Humans; D015848:Interleukin-5 / Q000037:antagonists & inhibitors*; D058990:Molecular Targeted Therapy / Q000379:methods; D053649:Receptors, Interleukin-5 / Q000037:antagonists & inhibitors
chemical_list: D018927:Anti-Asthmatic Agents; D061067:Antibodies, Monoclonal, Humanized; C508599:IL5 protein, human; D015848:Interleukin-5; D053649:Receptors, Interleukin-5; C515492:reslizumab; C571386:benralizumab; C434107:mepolizumab